These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 29602701)

  • 1. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans.
    Nivarthi UK; Swanstrom J; Delacruz MJ; Patel B; Durbin AP; Whitehead SS; Kirkpatrick BD; Pierce KK; Diehl SA; Katzelnick L; Baric RS; de Silva AM
    Nat Commun; 2021 Feb; 12(1):1102. PubMed ID: 33597521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
    Michlmayr D; Andrade P; Nascimento EJM; Parker A; Narvekar P; Dean HJ; Harris E
    J Infect Dis; 2021 Feb; 223(2):247-257. PubMed ID: 32572472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
    J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
    Metz SW; Thomas A; Brackbill A; Xianwen Y; Stone M; Horvath K; Miley MJ; Luft C; DeSimone JM; Tian S; de Silva AM
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006793. PubMed ID: 30248097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
    Wollner CJ; Richner M; Hassert MA; Pinto AK; Brien JD; Richner JM
    J Virol; 2021 May; 95(12):. PubMed ID: 33762420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
    Strouts FR; Popper SJ; Partidos CD; Stinchcomb DT; Osorio JE; Relman DA
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004731. PubMed ID: 27214236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.
    Sun W; Eckels KH; Putnak JR; Lyons AG; Thomas SJ; Vaughn DW; Gibbons RV; Fernandez S; Gunther VJ; Mammen MP; Statler JD; Innis BL
    J Infect Dis; 2013 Mar; 207(5):700-8. PubMed ID: 23225894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.
    Swanstrom JA; Henein S; Plante JA; Yount BL; Widman DG; Gallichotte EN; Dean HJ; Osorio JE; Partidos CD; de Silva AM; Baric RS
    J Infect Dis; 2018 May; 217(12):1932-1941. PubMed ID: 29800370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
    Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
    Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
    J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
    Henein S; Swanstrom J; Byers AM; Moser JM; Shaik SF; Bonaparte M; Jackson N; Guy B; Baric R; de Silva AM
    J Infect Dis; 2017 Feb; 215(3):351-358. PubMed ID: 27932620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine.
    Lin TH; Chen HW; Hsiao YJ; Yan JY; Chiang CY; Chen MY; Hu HM; Wu SH; Pan CH
    Front Immunol; 2020; 11():546. PubMed ID: 32300346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.
    Magnani DM; Silveira CGT; Ricciardi MJ; Gonzalez-Nieto L; Pedreño-Lopez N; Bailey VK; Gutman MJ; Maxwell HS; Domingues A; Costa PR; Ferrari L; Goulart R; Martins MA; Martinez-Navio JM; Fuchs SP; Kalil J; Timenetsky MDC; Wrammert J; Whitehead SS; Burton DR; Desrosiers RC; Kallas EG; Watkins DI
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28878078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.